Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4082148

O=C(O)C(F)(F)F.c1cc(-c2cnn(C3CCCCC3)c2)c2cc[nH]c2n1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.52
AURKB Q96GD4 1/20 0.52
INCENP Q9NQS7 1/20 0.52
TPX2 Q9ULW0 1/20 0.52
JAK1 P23458 14/20 0.51
GRM4 Q14833 1/20 0.48
JAK2 O60674 3/20 0.47
PIK3C3 Q8NEB9 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99743 0.90 AURKB (0.63) AURKAAURKBINCENPTPX2JAK1
SCHEMBL29541367 0.90 AURKB (0.63) AURKAAURKBINCENPTPX2JAK1
Trifluoroacetic Acid SCHEMBL4088967 0.89 AURKA (0.49) AURKAAURKBINCENPTPX2JAK1
SCHEMBL3375420 0.89 AURKB (0.64) AURKAAURKBINCENPTPX2JAK1
Trifluoroacetic Acid SCHEMBL4093616 0.87 AURKA (0.51) AURKAAURKBINCENPTPX2JAK1
Trifluoroacetic Acid SCHEMBL4093056 0.85 JAK1 (0.47) AURKAAURKBINCENPTPX2JAK1
Trifluoroacetic Acid SCHEMBL4095497 0.84 AURKA (0.47) AURKAAURKBINCENPTPX2JAK1
Trifluoroacetic Acid SCHEMBL4086857 0.84 JAK1 (0.51) AURKAAURKBINCENPTPX2JAK1
Trifluoroacetic Acid SCHEMBL4092066 0.80 AURKA (0.52) AURKAAURKBINCENPTPX2JAK1
SCHEMBL101352 0.79 AURKB (0.58) AURKAAURKBINCENPTPX2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130137681-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2013-05-30 US disclosed
US-8415362-B2 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2013-04-09 US disclosed
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137681-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 AURKA 485/4885AURKB 198/4885INCENP 4449/4885
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 AURKA 485/4885AURKB 198/4885INCENP 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.